Danielle Y. Sullivan, BS

Article

Eruptive Keratoacanthomas After Nivolumab Treatment of Stage III Melanoma

Author:

Danielle Y. Sullivan, BS

Eruptive keratoacanthomas (KAs) are a rare buttransient adverse effect of programmed cell death protein 1 (PD-1) inhibitor therapy.

• Read More